作者
Johannes Schwarzenberg, Johannes Czernin, Timothy F Cloughesy, Benjamin M Ellingson, Whitney B Pope, Tristan Grogan, David Elashoff, Cheri Geist, Daniel HS Silverman, Michael E Phelps, Wei Chen
发表日期
2014/7/1
期刊
Clinical Cancer Research
卷号
20
期号
13
页码范围
3550-3559
出版商
American Association for Cancer Research
简介
Purpose: This study compares the value of 3,4-dihydroxy-6-[18F]-fluoro-l-phenylalanine (18F-FDOPA) positron emission tomography (PET) and MRI in assessing outcome during antiangiogenic treatment in patients with recurrent high-grade gliomas.
Experimental Design: Thirty patients were prospectively studied with 18F-FDOPA PET scans immediately before, and two and six weeks after start of bevacizumab therapy. 18F-FDOPA metabolic tumor volumes (MTV) as well as max and mean standardized uptake values (SUV) within this MTV were obtained. MRI treatment response was assessed at six weeks. The predictive ability of 18F-FDOPA PET and MRI response assessment were evaluated with regard to progression-free survival (PFS) and overall survival (OS).
Results: A total of 30, 28, and 24 18F-FDOPA PET scans at baseline, two weeks, and six weeks, were available for …
引用总数
20142015201620172018201920202021202220232024561317181622141655